DNA-encoded library (DEL) technology has emerged as a powerful alternative to traditional phage and mRNA display methods for high-throughput peptide discovery. While biological display systems have enabled landmark discoveries, they remain constrained by their reliance on natural translation machinery, which limits access to unnatural amino acids and restricts cyclization strategies. BioDuro's latest innovations in DEL peptide chemistry directly address the technology's remaining limitations, potentially unlocking its full potential for peptide drug development.

The DEL Advantage for Peptide Discovery

DNA-encoded libraries fundamentally differ from biological display methods in their approach to peptide generation. Rather than relying on ribosomal translation, DEL employs combinatorial chemistry with DNA barcoding, where each unique peptide structure is covalently linked to an amplifiable DNA sequence that encodes its chemical identity. This architecture enables three critical advantages over biological systems.

The unrestricted access to unnatural amino acids and diverse cyclization chemistries translates directly to enhanced pharmacokinetic properties in DEL-derived peptides. N-methylated amino acids, D-amino acids, and other non-canonical residues can be incorporated to improve proteolytic stability, membrane permeability, and oral bioavailability -- modifications that biological display systems simply cannot achieve through translation.

The Split-and-Pool Synthesis Paradigm

DEL synthesis employs an elegant split-and-pool strategy that enables exponential library growth through iterative cycles of DNA tag ligation and building block addition. Starting material is distributed across multiple wells, where each well receives a unique DNA tag and corresponding chemical building block. After reaction completion, all products are pooled and redistributed for the next synthesis cycle. A typical 3–4 cycle synthesis can generate libraries containing billions of unique compounds from a few hundred building blocks per cycle.

DEL Screening Workflow

In affinity selection, up to hundreds of billions of DEL molecules are mixed in a single tube and incubated with immobilized target protein. After washing to remove unbound library members, the protein is denatured to release bound compounds into elution. This selection process is typically repeated 2–3 times against fresh target protein. The DNA tags of surviving hits are then amplified by PCR and decoded through next-generation sequencing to reveal their chemical structures -- a process that can identify potent binders from astronomical chemical space in days rather than months.

The Peptide Length Bottleneck

Despite DEL's theoretical advantages, a critical limitation has constrained its application to peptide discovery: most commercial DEL peptide libraries have been restricted to fewer than 10 amino acids, with many featuring only 2–5 residues. This limitation stems from small molecule-leaned coding scheme and practical challenges in on-DNA peptide synthesis, where coupling efficiency, side reactions, and purification difficulties compound with each additional residue.

BioDuro's research team, led by Yihui Xie at the company's Beijing facility, has directly addressed this bottleneck through two complementary innovations.

Expanding Macrocyclization Chemistry

Beyond the established CuAAC, disulfide and thioether formation reactions used in published DEL peptide libraries, the field has developed numerous additional macrocyclization strategies compatible with on-DNA synthesis conditions.

This expanding toolkit of cyclization chemistries enables DEL peptide libraries to explore diverse macrocyclic architectures -- bicyclic, polycyclic, and hybrid scaffolds incorporating both peptidic and non-peptidic elements -- that are inaccessible through biological display methods.

Addressing the Peptide Drug Discovery Bottleneck

The peptide therapeutics market, currently valued at over $50 billion and projected to reach $70 billion by 2030, faces a fundamental discovery challenge: identifying peptides that combine target potency with favorable pharmacokinetic properties. Traditional approaches -- starting from endogenous peptide hormones or phage display hits and iteratively optimizing through medicinal chemistry -- are time-consuming and often fail to achieve adequate oral bioavailability or metabolic stability.

DEL peptide technology, enhanced by BioDuro's innovations, offers an alternative paradigm: screening libraries that already incorporate stability-enhancing modifications, thereby identifying hits with favorable properties rather than engineering them retrospectively. The ability to include D-amino acids, N-methylated residues, and diverse cyclization constraints from the outset fundamentally changes the hit identification starting point.

Competitive Positioning

The DEL services market has grown substantially, with major pharmaceutical companies either building internal DEL capabilities or partnering with specialized providers. BioDuro's positioning in this space emphasizes peptide-specific innovations that address limitations not fully solved by competitors focused primarily on small molecule DEL applications.

The 108-channel building block synthesis capability and demonstrated 10-mer DEL macrocycle synthesis establish technical differentiation in a market where peptide DEL offerings have historically been constrained to shorter, simpler structures. For pharmaceutical clients seeking peptide leads against challenging targets -- particularly protein-protein interactions where larger binding surfaces favor longer peptides -- BioDuro's extended-length capabilities offer unique value.

Bridging Chemical Space Gaps

The DEL peptide field has operated with a significant gap between the structural complexity achievable in phage display (which readily produces 7–15mer peptides but restricts chemistry) and traditional DEL (which offers full chemical flexibility but has been practically limited to short peptides). BioDuro's work directly addresses this gap, demonstrating that chemical flexibility and substantial peptide length are not mutually exclusive.

The inclusion of D-amino acids, N-methylated residues, and other non-canonical amino acids in the expanding oligopeptide building block collection is particularly significant. These modifications represent the primary medicinal chemistry strategies for improving peptide drug-likeness, and their incorporation into DEL building blocks enables discovery of optimized peptides rather than leads requiring extensive modification.

Quality Control Advantages

A frequently underappreciated DEL advantage is library quality control. Unlike phage or mRNA display, where library composition can only be assessed through deep sequencing of DNA encoding sequences, DEL libraries can be directly characterized through mass spectrometry and chromatography. The high crude purity achieved by BioDuro's 10-mer on-DNA macrocycle synthesis -- >50% with clear peak shift of cyclized product -- demonstrates that quality control standards achievable in traditional peptide synthesis can be maintained in the DEL context.

Expanding the Building Block Repertoire

BioDuro's ongoing work focuses on expanding the oligopeptide building block collection to include D-amino acids, N-methylated amino acids, and other non-canonical residues. This expansion will enable DEL peptide libraries with built-in stability enhancements, identifying hits that already possess favorable pharmacokinetic properties rather than requiring extensive post-selection optimization.

Library Scale and Diversity

With oligopeptide building blocks enabling effective incorporation of 5 amino acids per synthesis cycle, a 4-cycle DEL synthesis could theoretically produce libraries featuring 20-mer peptides with billions of unique sequences. Cyclization will further increase their diversity in terms of ring number, size, and position. Realizing this potential will require optimization of coupling conditions, development of additional cyclization chemistries, and validation that library quality can be maintained at these increased complexity levels.

Target Class Expansion

The demonstrated potencies of existing DEL peptide hits -- single-digit nanomolar affinities for challenging targets like MDM2 and AT1R -- suggest significant untapped potential for target classes where peptides offer intrinsic advantages. Intracellular protein-protein interactions, epigenetic readers like chromodomains, and allosteric binding sites with extended binding surfaces represent particularly attractive opportunities for DEL peptide campaigns enabled by longer, more complex library members.

BioDuro's innovations in DNA-encoded peptide library technology address the critical bottlenecks that have limited the platform's application to peptide drug discovery. The 108-channel automated synthesis system producing high-purity oligopeptide building blocks, combined with on-DNA segment ligation capability demonstrated by a 10-mer macrocycle synthesis, substantially expands the structural complexity accessible to DEL selections.

For peptide drug discovery programs, these advances offer a compelling value proposition: the ability to screen billions of macrocyclic peptides incorporating stability-enhancing non-canonical amino acids, identifying hits with favorable pharmacokinetic properties rather than engineering them through iterative optimization. As the technology matures and building block diversity expands, DEL peptide libraries may increasingly complement or replace traditional display methods for therapeutic peptide discovery, particularly for challenging targets requiring larger, more complex peptide architectures.

The field stands at an inflection point where the chemical flexibility that has always been DEL's theoretical advantage is becoming practically achievable for peptide applications, potentially reshaping how the next generation of peptide therapeutics is discovered.